Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

21. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. (PubMed)

Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence.To determine efficacy and safety of varenicline and bupropion sustained-release (SR; combination therapy) compared with varenicline (monotherapy) in cigarette smokers.Randomized, blinded, placebo-controlled multicenter clinical trial with a 12-week treatment period and follow-up through (...) week 52 conducted between October 2009 and April 2013 at 3 midwestern clinical research sites. Five hundred six adult (≥18 years) cigarette smokers were randomly assigned and 315 (62%) completed the study.Twelve weeks of varenicline and bupropion SR or varenicline and placebo.Primary outcome was abstinence rates at week 12, defined as prolonged (no smoking from 2 weeks after the target quit date) abstinence and 7-day point-prevalence (no smoking past 7 days) abstinence. Secondary outcomes were

Full Text available with Trip Pro

2014 JAMA

22. Effects of Naltrexone Sustained- Release/Bupropion Sustained Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes (PubMed)

Effects of Naltrexone Sustained- Release/Bupropion Sustained Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs.This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized

Full Text available with Trip Pro

2013 EvidenceUpdates

23. Prolonged release naltrexone and bupropion (Contrave) for the management of obesity

Prolonged release naltrexone and bupropion (Contrave) for the management of obesity Prolonged release naltrexone and bupropion (Contrave) for the management of obesity Prolonged release naltrexone and bupropion (Contrave) for the management of obesity NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Prolonged release (...) naltrexone and bupropion (Contrave) for the management of obesity. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Naltrexones; Narcotic Antagonists; Obesity; Weight Loss Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning

2013 Health Technology Assessment (HTA) Database.

24. Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments Executive Summary 1 Translation of the executive summary of the final report “Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen” (Version 1.0; Status: 3 September 2013). Please note: This translation is provided as a service by IQWiG to English-language (...) readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. G09-01 Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments 1 Executive summary of final report G09-01 Version 1.0 Health economic evaluation of venlafaxine, duloxetine, bupropion, mirtazapine 3 Sep 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

25. Review: Varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults. (PubMed)

Review: Varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults. 22986399 2012 12 03 2012 09 18 1539-3704 157 6 2012 Sep 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults. JC3-7 10.7326/0003-4819-157-6-201209180-02007 Prochazka Allan V AV Caverly Tanner J TJ eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 Cochrane

2012 Annals of Internal Medicine

26. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation (PubMed)

Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation The purpose of this systematic review was to review the cost-effectiveness of first-line non-nicotine therapies (varenicline and bupropion SR) for smoking cessation, identify differences in the models used and their conclusions of cost-effectiveness, and to determine which variables, if any, impact conclusions of cost-effectiveness. A systematic literature search was conducted in MEDLINE, PsychINFO (...) , the National Health Service Economic Evaluation Database, the Health Technology Database and the Tufts Cost-effectiveness Analysis Registry from the earliest possible date through May 2011. To be included, studies had to compare cost-effectiveness of varenicline to bupropion using either a Markov model or discrete event simulation and be published as a full text manuscript in English or Spanish. Study selection and data extraction were done in duplicate with disagreement resolved through discussion. Data

2012 EvidenceUpdates

27. Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome (PubMed)

Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome Smokers hospitalized with acute coronary syndrome (ACS) are at high risk for subsequent ischemic events. Nevertheless, over two-thirds of patients continue to smoke after an acute myocardial infarction. Bupropion hydrochloride has proven efficacy as a smoking cessation aid, but data regarding its safety and efficacy in ACS patients are limited.In a double-blind, randomized controlled trial, we compared the safety (...) and efficacy of 8 weeks of treatment with bupropion slow-release (SR) or placebo for smokers hospitalized with ACS as an adjunct to nurse-led hospital- and telephone-based support. Primary efficacy outcome was smoking abstinence at 1 year. Primary safety outcome was clinical events at 1 year.A total of 151 patients were enrolled; all but 2 completed follow-up. Abstinence rates at 3 months were 45% and 44% in the bupropion SR and placebo groups, respectively (P = .99); 37% vs 42% (P = .61) at 6 months

Full Text available with Trip Pro

2011 EvidenceUpdates

28. Forfivo XL (bupropion hydrochloride 450 mg extended-release) tablets

Forfivo XL (bupropion hydrochloride 450 mg extended-release) tablets Drug Approval Package: Forfivo XL (bupropion hydrochloride) NDA #022497 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - FORFIVO XL (bupropion hydrochloride 450 mg extended-release) tablets Company: IntelGenx Corp Application No.: 022497 Approval Date: 11/10/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

2011 FDA - Drug Approval Package

29. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.1; Status: 30.05.2011). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression 30.05.2011 Institute for Quality and Efficiency in Health Care (IQWiG) Version 1.1 - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal

2011 Institute for Quality and Efficiency in Healthcare (IQWiG)

30. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis (PubMed)

Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis The benefits and harms of bupropion as an aid for smoking cessation in schizophrenia remain uncertain.To summarise the current evidence for efficacy and safety of bupropion as treatment for nicotine dependence in schizophrenia.Systematic review and random-effects meta-analysis of randomised controlled trials (RCTs) comparing bupropion with placebo or alternative therapeutic (...) control in adult smokers with schizophrenia.Twenty-one reports from seven RCTs were included. Biochemically verified self-reported smoking cessation rates after bupropion were significantly higher than placebo at the end of treatment (risk ratio (RR) = 2.57, P = 0.004) and at 6 months (RR = 2.78, P = 0.05). Expired carbon monoxide level was significantly lower with bupropion at the end of therapy (P = 0.002) but not at 6 months (P = 0.37). There was no significant difference in positive (P = 0.28

Full Text available with Trip Pro

2010 EvidenceUpdates

31. Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined. (PubMed)

Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined. 20436150 2010 05 05 2017 01 23 1468-9618 13 2 2010 Apr Evidence-based nursing Evid Based Nurs Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine

2010 Evidence-Based Nursing

32. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (PubMed)

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Despite increasing public health concerns regarding obesity, few safe and effective drug treatments are available. Combination treatment with sustained-release naltrexone and bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight. The Contrave Obesity Research I (COR-I) study assessed (...) naltrexone 32 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB32), sustained-release naltrexone 16 mg per day plus sustained-release bupropion 360 mg per day combined in fixed-dose tablets (also known as NB16), or matching placebo twice a day, given orally for 56 weeks. The trial included a 3-week dose escalation. Randomisation was done by use of a centralised, computer-generated, web-based system and was stratified by study centre. Co-primary

2010 Lancet

33. Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder

Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after (...) the failure of an SSRI for major depressive disorder Leelahanaj T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of switching from citalopram to bupropion monotherapy versus bupropion in addition

2010 NHS Economic Evaluation Database.

34. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomaki T Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of varenicline compared with bupropion or no aid for smoking cessation in Finland. The authors concluded that varenicline was more effective and resulted in cost savings

2010 NHS Economic Evaluation Database.

35. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse

Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions RCTs examining the efficacy of bupropion in adult ADHD frequently reported

2010 Health Technology Assessment (HTA) Database.

36. Use of bupropion in patients with depression and the associated risk of seizures: safety

Use of bupropion in patients with depression and the associated risk of seizures: safety Use of bupropion in patients with depression and the associated risk of seizures: safety Use of bupropion in patients with depression and the associated risk of seizures: safety Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Use of bupropion in patients with depression and the associated risk of seizures: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions The available evidence of an increased risk of seizures in patients treated with bupropion for depression was inconclusive. This evidence was, however, limited to uncontrolled studies rated as low quality by the authors of the AHRQ

2010 Health Technology Assessment (HTA) Database.

37. Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia

Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Article Text Therapeutics Review: bupropion increases

Full Text available with Trip Pro

2010 Evidence-Based Mental Health

38. Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months

Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 monthsCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 monthsCommentary Article

2010 Evidence-Based Nursing

39. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.0; Status: 09.11.2009). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression Version 1.0 09.11.2009 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal Commission No.: A05-20C Publisher’s address: Institute for Quality

2009 Institute for Quality and Efficiency in Healthcare (IQWiG)

40. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Hoogendoorn M, Welsing P, Rutten-van Molken M P Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the long-term cost-effectiveness of varenicline to support smoking cessation in comparison with no treatment, bupropion, nortriptyline, or nicotine-replacement therapy (NRT). The authors concluded that varenicline was cost-effective compared

2008 NHS Economic Evaluation Database.